10 completed, 1 unknown. 6 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Unknown 1 |
| Phase 1 | 5 | Completed 5 |
Follow Celon Pharma SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis CPL409116, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Celon Pharma SA | 106 | 2022-05-01 | 2025-01-23 |
| Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes CPL207280, Placebo - Type 2 Diabetes | Phase 2 | Unknown | Celon Pharma SA | 80 | 2022-01-21 | 2023-02-08 |
| Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia CPL500036 - low dose, CPL500036 - high dose, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Completed | Celon Pharma SA | 105 | 2021-11-02 | 2025-03-04 |
| Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia CPL500036 - low dose, CPL500036 - high dose, Placebo - Schizophrenia | Phase 2 | Completed | Celon Pharma SA | 189 | 2021-05-19 | 2025-09-10 |
| Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers CPL409116, Placebo - Healthy | Phase 1 | Completed | Celon Pharma SA | 65 | 2020-12-08 | 2022-05-16 |
| Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers. CPL207280, Placebo, Metformin hydrochloride 750 mg - Healthy Volunteers | Phase 1 | Completed | Celon Pharma SA | 68 | 2020-05-27 | 2021-08-18 |
| Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies CPL304110 - Gastric Cancer, Bladder Cancer | Phase 1 | Completed | Celon Pharma SA | 37 | 2019-07-19 | 2026-10-29 |
| Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose - Bipolar Depression | Phase 2 | Completed | Celon Pharma SA | 88 | 2019-03-28 | 2021-03-19 |
| Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose - Major Depressive Disorder | Phase 2 | Completed | Celon Pharma SA | 88 | 2019-02-25 | 2020-04-28 |
| Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers CPL500036 compound, Placebo - Healthy Volunteers | Phase 1 | Completed | Celon Pharma SA | 56 | 2018-12-20 | 2019-10-04 |
| Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers Esketamine DPI, Placebo DPI - Healthy Volunteers | Phase 1 | Completed | Celon Pharma SA | 63 | 2017-12-09 | 2018-07-12 |
Arthritis, Rheumatoid (1) · Bipolar Disorder (1) · Carcinoma (1) · Cholangiocarcinoma (1) · Depressive Disorder, Major (1) · Diabetes Mellitus, Type 2 (1) · Dyskinesia, Drug-Induced (1) · Endometrial Neoplasms (1) · Neoplasms (1) · Parkinson Disease (1) · Sarcoma (1) · Schizophrenia (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Poland (11) · Ukraine (3) · Hungary (1)
PMID 33199155, PMID 34349026, PMID 34510411, PMID 40235539, PMID 40516565, PMID 42533223